Hello, Subscribers:
There are countless investors who are hoping, if not praying, that the correction which has suddenly hit the U.S. stock market since mid-February is not the start of a 2022-type bear market.
Actually, for the already beaten-down sectors, such as energy and healthcare (especially, pharmaceuticals), that may be true. However, when it comes to the ultra-high P/E stocks, which are heavily represented in the S&P 500 Momentum Index, it might be a case of wishful — maybe even delusional — thinking.